Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
Conditions: Prostate Cancer; Erectile DysfunctionInterventions: Drug: sildenafil citrate and questionaires; Drug: placebo tablets and questionairesSponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Mount Sinai School of Medicine; Beth Israel Medical Center; St. Luke's-Roosevelt Hospital CenterActive, not recruiting - verified April 2013
AbstractPurpose of ReviewThis review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer.Recent FindingsThe phase 3 STAMPEDE trial showed that prostate radiotherapy confers a survival benefit for newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer (HSPC). No survival benefit was noted for those with high volume disease. A subsequent meta-analysis combining the data of the STAMPEDE trial with that of the HORRAD trial corroborated these findings. The phase 2 randomized STOMP trial investigated local treatment of metastases in patients with oligo...
To identify variables that predict persistent hypogonadism and castration in patients with prostate cancer (PCa) treated with brachytherapy (BT).
ABSTRACT Introduction: Tables predicting the probability of a positive bone scan in men with non-metastatic, castrate-resistant prostate cancer have recently been reported. We performed an external validation study of these bone scan positivity tables. Materials and Methods: We performed a retrospective cohort study of patients seen at a tertiary care medical center (1996-2012) to select patients with non-metastatic, castrate-resistant prostate cancer. Abstracted data included demographic, anthropometric, and disease-specific data such as patient race, BMI, PSA kinetics, and primary treatment. Primary outcome was metastasi...
Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and for prostate cancer. Serum concentrations of oestradiol and testosterone are controlled by the hypothalamic-pituitary-gonadal pathway. Oestradiol is produced in premenopausal women from the ovaries, and in postmenopausal women by peripheral conversion of adrenal androgens by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is primarily achieved by castration.
Title: Prostate Cancer Treatment: Hormonal TherapyCategory: Diseases and ConditionsCreated: 1/9/2020 12:00:00 AMLast Editorial Review: 1/9/2020 12:00:00 AM
CONCLUSIONS: Developmentally reprogrammed PCa cell models recapitulate features of clinically-advanced prostate tumors including downregulated Rb1/p53 and overexpression of Sox2 with Sox9. Sox9 is a marker of a transitional state that identifies PCa cells under the stress of therapeutic assault and facilitates progression to therapy resistance. Its expression may index the relative activity of the NF-κB pathway. PMID: 31919137 [PubMed - as supplied by publisher]
Conditions: Prostate Cancer; Chemotherapy Effect; Hormone Sensitive Prostate Cancer; Locally Advanced Prostate Carcinoma Interventions: Drug: Neoadjuvant chemotherapy combined with hormone therapy; Drug: Neoadjuvant hormone therapy; Procedure: Radical Prostatectomy (RP)+ extended lymph node dissection Sponsor: RenJi Hospital Not yet recruiting
New England Journal of Medicine,Volume 381, Issue 26, Page 2564-2566, December 2019.
This study is a multicentre, randomised, open-label, phase 3 trial. Patients with localised prostate cancer whose PSA concentrations had decreased to